Another biotech grabs the axe, chopping R&D in a major reorganization as drug sales disappoint

Heron Therapeutics has been sorely tested in its transition from an R&D company to a commercialization focus, losing 70% of its market cap $HRTX in Nasdaq’s storm-tossed waters since the beginning of the year.